Alnylam Pharmaceuticals, Inc.
ALNY Real Time Price USDRecent trades of ALNY by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ALNY holdings by institutional investors
Quarterly net insider trading by ALNY's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$390,000 Oct 20, 2025 Issue: Medicare/Medicaid Trade (domestic/foreign) Pharmacy
-
$390,000 Jul 20, 2025 Issue: Medicare/Medicaid Trade (domestic/foreign)
-
$440,000 Apr 21, 2025 Issue: Medicare/Medicaid Veterans
-
$500,000 Jan 21, 2025 Issue: Medicare/Medicaid Veterans
-
$480,000 Oct 21, 2024 Issue: Veterans Medicare/Medicaid
-
$480,000 Jul 22, 2024 Issue: Veterans Medicare/Medicaid
-
$290,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$220,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$220,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$50,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$50,000 Jul 20, 2023 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$60,000 Jul 14, 2023 Issue: Medicare/Medicaid
-
$50,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$50,000 Jan 20, 2023 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$100,000 Jan 14, 2023 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2022 Issue: Medicare/Medicaid
-
$60,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$60,000 Oct 16, 2022 Issue: None
-
$50,000 Jul 20, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$50,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Jul 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jul 15, 2022 Issue: None
-
$40,000 Jul 15, 2022 Issue: Medicare/Medicaid
-
$60,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Apr 19, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$40,000 Apr 15, 2022 Issue: None
-
$40,000 Apr 14, 2022 Issue: Medicare/Medicaid
-
$50,000 Jan 20, 2022 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Jan 19, 2022 Issue: Medicare/Medicaid
-
$40,000 Jan 13, 2022 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Oct 15, 2021 Issue: Medicare/Medicaid Health Issues
-
$40,000 Oct 14, 2021 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jul 20, 2021 Issue: Medicare/Medicaid
-
$40,000 Jul 13, 2021 Issue: Medicare/Medicaid
-
$50,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$60,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$30,000 Apr 13, 2021 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 12, 2021 Issue: Medicare/Medicaid
-
$30,000 Jan 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jan 20, 2021 Issue: Medicare/Medicaid
-
$50,000 Jan 19, 2021 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 16, 2020 Issue: Medicare/Medicaid
-
$50,000 Oct 14, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 06, 2020 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid Taxation/Internal Revenue Code
-
$30,000 Jul 15, 2020 Issue: Medicare/Medicaid
-
$50,000 Jul 15, 2020 Issue: Medicare/Medicaid
-
$30,000 Jul 14, 2020 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 20, 2020 Issue: Medicare/Medicaid
-
$50,000 Apr 19, 2020 Issue: Medicare/Medicaid
-
$30,000 Apr 17, 2020 Issue: Health Issues Medicare/Medicaid
-
$50,000 Apr 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$50,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$60,000 Jan 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 21, 2019 Issue: Medicare/Medicaid
-
$50,000 Oct 21, 2019 Issue: Medicare/Medicaid
-
$40,000 Oct 21, 2019 Issue: Medicare/Medicaid
-
$20,000 Oct 21, 2019 Issue: Health Issues
-
$30,000 Jul 22, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 22, 2019 Issue: Health Issues
-
$50,000 Jul 22, 2019 Issue: Medicare/Medicaid
-
$50,000 Jul 16, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 22, 2019 Issue: Medicare/Medicaid
-
$50,000 Apr 22, 2019 Issue: Medicare/Medicaid
-
$40,000 Apr 22, 2019 Issue: Medicare/Medicaid
-
$40,000 Apr 22, 2019 Issue: Health Issues
-
$30,000 Jan 22, 2019 Issue: Medicare/Medicaid
-
$40,000 Jan 22, 2019 Issue: Health Issues
-
$30,000 Jan 22, 2019 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2019 Issue: Health Issues
-
$40,000 Oct 22, 2018 Issue: Health Issues
-
$30,000 Oct 22, 2018 Issue: Medicare/Medicaid
-
$30,000 Oct 22, 2018 Issue: Health Issues
-
$30,000 Oct 19, 2018 Issue: Medicare/Medicaid
-
$40,000 Jul 20, 2018 Issue: Health Issues
-
$30,000 Jul 19, 2018 Issue: Health Issues
-
$40,000 Apr 20, 2018 Issue: Health Issues
-
$30,000 Apr 20, 2018 Issue: Health Issues
-
$20,000 Jan 22, 2018 Issue: Health Issues
-
$40,000 Jan 22, 2018 Issue: Health Issues
-
$40,000 Oct 20, 2017 Issue: Health Issues
-
$40,000 Jul 20, 2017 Issue: Health Issues
-
$30,000 Jul 20, 2017 Issue: Medicare/Medicaid Health Issues
-
$30,000 Apr 20, 2017 Issue: Medicare/Medicaid Health Issues
-
$40,000 Apr 20, 2017 Issue: Health Issues
-
$40,000 Jan 23, 2017 Issue: Health Issues
-
$30,000 Jan 19, 2017 Issue: Medicare/Medicaid Health Issues
-
$40,000 Oct 26, 2016 Issue: Health Issues
ALNY Estimated quarterly lobbying spending
ALNY Revenue by Segment or Geography
New ALNY patent grants
-
Patent Title: Pegylated lipids and their use for drug delivery Jun. 19, 2018
-
Patent Title: Conserved hbv and hcv sequences useful for gene silencing May. 29, 2018
-
Patent Title: Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes May. 15, 2018
-
Patent Title: Gnaq targeted dsrna compositions and methods for inhibiting expression May. 08, 2018
-
Patent Title: Compositions and methods for inhibiting expression of mutant egfr gene May. 01, 2018
-
Patent Title: Compositions and methods directed to treating liver fibrosis Apr. 17, 2018
-
Patent Title: Compositions and methods for inhibiting expression of cd274/pd-l1 gene Apr. 03, 2018
-
Patent Title: Method and medicament for inhibiting the expression of a given gene Feb. 27, 2018
-
Patent Title: Serpina1 sirnas: compositions of matter and methods of treatment Jan. 30, 2018
-
Patent Title: Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene Jan. 16, 2018
-
Patent Title: Carbohydrate conjugates as delivery agents for oligonucleotides Jan. 16, 2018
-
Patent Title: Complement component c5 irna compositions and methods of use thereof Dec. 26, 2017
-
Patent Title: Compositions and methods for inhibiting expression of the pcsk9 gene Nov. 21, 2017
-
Patent Title: Modified rnai agents Oct. 24, 2017
-
Patent Title: Tmprss6 irna compositions and methods of use thereof Oct. 10, 2017
-
Patent Title: Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof Sep. 26, 2017
-
Patent Title: Compositions and methods for inhibition of expression of protein c (proc) genes Aug. 08, 2017
-
Patent Title: Therapeutic compositions Jul. 18, 2017
-
Patent Title: Modified rnai agents Jul. 18, 2017
-
Patent Title: Complement component c5 irna compositions and methods of use thereof Jul. 11, 2017
-
Patent Title: Di-aliphatic substituted pegylated lipids Jul. 11, 2017
-
Patent Title: Nucleic acid lipid particle formulations Jun. 27, 2017
-
Patent Title: Biodegradable lipids for the delivery of active agents Jun. 20, 2017
-
Patent Title: Compositions and methods for inhibiting expression of the alas1 gene Apr. 25, 2017
-
Patent Title: Compositions and methods for inhibiting expression of a target gene Mar. 07, 2017
-
Patent Title: Serapina1 irna compositions and methods of use thereof Feb. 21, 2017
-
Patent Title: Monomers and oligonucleotides comprising cycloaddition adduct(s) Feb. 14, 2017
-
Patent Title: Gnaq targeted dsrna compositions and methods for inhibiting expression Feb. 14, 2017
-
Patent Title: Oligonucleotide end caps Dec. 06, 2016
-
Patent Title: Compositions and methods for inhibiting expression of the hamp gene Nov. 29, 2016
-
Patent Title: Irna agents with biocleavable tethers Oct. 25, 2016
-
Patent Title: Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents Oct. 11, 2016
-
Patent Title: Ligand-conjugated monomers Sep. 27, 2016
-
Patent Title: Nucleic acid chemical modifications Sep. 27, 2016
-
Patent Title: Compositions and methods for inhibiting expression of factor v Sep. 13, 2016
-
Patent Title: Compositions and methods for inhibiting expression of cd274/pd-l1 gene Aug. 23, 2016
-
Patent Title: Stable non-aggregating nucleic acid lipid particle formulations Aug. 16, 2016
-
Patent Title: Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases Jul. 26, 2016
-
Patent Title: Modified irna agents Jul. 19, 2016
-
Patent Title: Serpinc1 irna compositions and methods of use thereof Jun. 28, 2016
-
Patent Title: Carbohydrate conjugates as delivery agents for oligonucleotides Jun. 21, 2016
-
Patent Title: Carbohydrate conjugates as delivery agents for oligonucleotides Jun. 21, 2016
-
Patent Title: Carbohydrate conjugates as delivery agents for oligonucleotides May. 31, 2016
-
Patent Title: Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes May. 17, 2016
-
Patent Title: Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof Apr. 26, 2016
-
Patent Title: Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes Apr. 19, 2016
-
Patent Title: Modified irna agents Mar. 22, 2016
-
Patent Title: Compositions and methods for inhibiting expression of the pcsk9 gene Feb. 16, 2016
-
Patent Title: Methods and compositions for delivery of active agents Feb. 09, 2016
-
Patent Title: Complement component c5 irna compositions and methods of use thereof Feb. 02, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ALNY from public contracts
Recent insights relating to ALNY
Recent picks made for ALNY stock on CNBC
ETFs with the largest estimated holdings in ALNY
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ALNY stock a Buy, Sell, or Hold?
- What is the price target for $ALNY stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ALNY stock?
- Who owns the most shares of $ALNY stock?
- What funds own $ALNY stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALNY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
- Address Cambridge, MA
- Market Cap 57.7 billion
- Employees 2,230
- Industrial Classification Pharmaceutical Preparations